149 related articles for article (PubMed ID: 37672238)
1. Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
Ellis MS; Xu KY; Tardelli VS; Fidalgo TM; Buttram ME; Grucza RA
JAMA Psychiatry; 2023 Dec; 80(12):1269-1276. PubMed ID: 37672238
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.
Mintz CM; Xu KY; Presnall NJ; Hartz SM; Levin FR; Scherrer JF; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211634. PubMed ID: 35544135
[TBL] [Abstract][Full Text] [Related]
3. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
5. Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk.
Tardelli V; Xu KY; Bisaga A; Levin FR; Fidalgo TM; Grucza RA
BMJ Ment Health; 2023 Jul; 26(1):. PubMed ID: 37500184
[TBL] [Abstract][Full Text] [Related]
6. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
[TBL] [Abstract][Full Text] [Related]
8. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
9. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
11. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
12. Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.
Xu KY; Borodovsky JT; Presnall N; Mintz CM; Hartz SM; Bierut LJ; Grucza RA
Am J Psychiatry; 2021 Jul; 178(7):651-659. PubMed ID: 33653119
[TBL] [Abstract][Full Text] [Related]
13. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
[TBL] [Abstract][Full Text] [Related]
14. Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.
Ellis MS; Buttram ME; Kasper ZA
Drug Alcohol Depend; 2022 May; 234():109400. PubMed ID: 35290917
[TBL] [Abstract][Full Text] [Related]
15. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
[TBL] [Abstract][Full Text] [Related]
17. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
[TBL] [Abstract][Full Text] [Related]
18. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
[TBL] [Abstract][Full Text] [Related]
19. Benzodiazepine, Z-drug, and sleep medication prescriptions in male and female people with opioid use disorder on buprenorphine and comorbid insomnia: an analysis of multistate insurance claims.
Martin CE; Patel H; Dzierewski JM; Moeller FG; Bierut LJ; Grucza RA; Xu KY
Sleep; 2023 Jun; 46(6):. PubMed ID: 36970994
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]